Verisante Chosen as "Pick of the Street" in the Technology and Life Sciences Sector
VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 5, 2012) - Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF)(PINKSHEETS:VRSEF)(FRANKFURT:V3T) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today that the Company was named the "Pick of the Street" in the Technology and Life Sciences Sector of the TSX Venture Exchange.
Following the official announcement of the 2012 TSX Venture 50 in February, in which Verisante was named the top Technology and Life Sciences Company, a selection of Canada's professional investment community, including Fund managers, analysts, bankers, and retail brokers were polled by Investor Relations firm, Equicom Group, to select the "Pick of the Street" in each Venture 50 sector.
The "Pick of the Street" awards were announced at the TSX Venture 50 Spotlight event on April 3, 2012 in Toronto, where Verisante made a presentation to an audience comprised of portfolio managers, investment bankers, research analysts and investment advisors.
"We very much appreciate the recognition by the Canadian investment community," said Thomas Braun, President and CEO. "With our Canadian distributor in place and our Beta units currently in the process of being tested and placed, Verisante continues to meet our key business milestones as we work towards helping healthcare providers save lives through the detection of some of the most common forms of cancer."
About Verisante Technology, Inc.
Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. The Aura™ has been approved for sale in Canada, Europe and Australia. The Core™ has not yet been approved for sale.
Verisante Aura™ was recently awarded Popular Science Magazine's "Best of What's New Award" for 2011, and Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society. In addition, the Company was named a finalist for the 2011 Regional Awards for New Technology by the Canadian Manufacturers & Exporters and the National Research Council of Canada and named as the year's top ranking Technology and Life Sciences Company on the TSX Venture 50.
Forward-Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
Following the official announcement of the 2012 TSX Venture 50 in February, in which Verisante was named the top Technology and Life Sciences Company, a selection of Canada's professional investment community, including Fund managers, analysts, bankers, and retail brokers were polled by Investor Relations firm, Equicom Group, to select the "Pick of the Street" in each Venture 50 sector.
The "Pick of the Street" awards were announced at the TSX Venture 50 Spotlight event on April 3, 2012 in Toronto, where Verisante made a presentation to an audience comprised of portfolio managers, investment bankers, research analysts and investment advisors. "We very much appreciate the recognition by the Canadian investment community," said Thomas Braun, President and CEO. "With our Canadian distributor in place and our Beta units currently in the process of being tested and placed, Verisante continues to meet our key business milestones as we work towards helping healthcare providers save lives through the detection of some of the most common forms of cancer."
About Verisante Technology, Inc.
Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. The Aura™ has been approved for sale in Canada, Europe and Australia. The Core™ has not yet been approved for sale.
Verisante Aura™ was recently awarded Popular Science Magazine's "Best of What's New Award" for 2011, and Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society. In addition, the Company was named a finalist for the 2011 Regional Awards for New Technology by the Canadian Manufacturers & Exporters and the National Research Council of Canada and named as the year's top ranking Technology and Life Sciences Company on the TSX Venture 50.
Forward-Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.